Business News • PR NewsWire • Abbott Announces New Long-Term Data Evaluating Use of HUMIRA® (Adalimumab) for Patients with Long-Standing Moderate to Severe Rheumatoid Arthritis and for Patients with Early Moderate to Severe RA

Abbott Announces New Long-Term Data Evaluating Use of HUMIRA® (Adalimumab) for Patients with Long-Standing Moderate to Severe Rheumatoid Arthritis and for Patients with Early Moderate to Severe RA

Abbott Announces New Long-Term Data Evaluating Use of HUMIRA® (Adalimumab) for Patients with Long-Standing Moderate to Severe Rheumatoid Arthritis and for Patients with Early Moderate to Severe RA

ABBOTT PARK, Ill., Nov. 6, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from long-term open-label extensions of the PREMIER and DE019 Phase 3 studies, which evaluated HUMIRA® (adalimumab) plus methotrexate (MTX) for up to eight years in patients with early moderate...

View More : http://www.prnewswire.com/news-releases/abbott-announces-new-long-term-data-evaluating-use-of-humira-adalimumab-for-pati...

Releted News by prnewswire

Simbionix stellt drei neue Produkte für die Frauenheilkunde vor

Rentrak Announces Official Box Office Numbers for Weekend of November 4, 2011

Simbionix to Introduce Three New Women's Health Products